First batch of blood samples has been tested for prospective clinical trials using the Guardant360® liquid biopsy in the Adicon laboratory in China
May 16, 2024
HANGZHOU, China — Adicon Holdings Limited, a leading independent clinical laboratory company, announced today that it has completed processing the first batch of blood samples using the Guardant360® liquid biopsy test for prospective clinical trials which will help to accelerate the enrollment of patients and advance drug development in China. This blood-based test provides biopharmaceutical companies with access to comprehensive genomic profiling, also known as tumour mutation profiling, in patients with advanced solid cancers. Analytical Validation (AV) studies of Guardant Health’s Guardant360 test conducted by Adicon in China demonstrate that the performance of the test in its Shanghai Jince Medical Laboratory is equivalent to the performance in Guardant Health’s US-based laboratory.
“The Adicon laboratory is delighted to announce that the first batch of blood samples has been successfully tested using Guardant360 for enrolling patients in clinical trials and we are confident that this comprehensive genomic profiling test can help accelerate clinical trials and development of new cancer therapies in China,” said Song Gao, CEO of Adicon.
About Adicon
Adicon is one of the leading independent clinical laboratory (ICL) networks in China. We offer comprehensive and best-in-class testing services primarily to hospitals and health check centres as well as central laboratory services to biopharma clients and contract research organizations through an integrated network of 36 self-operated laboratories across China. Currently, we have 20 of our laboratories accredited by ISO15189, which enabled us to provide customers with the quality assurance that comes with this rigorous international standard. Our testing portfolio consists of over 4,000 medical diagnostic tests, including over 1,700 routine tests and over 2,300 esoteric tests. We are committed to continuously serving patients and the general public with our high-quality testing services as a leading ICL service provider in China and becoming a trusted and reliable partner for medical professionals and
the general public.